XML 18 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 9 Months Ended
Jun. 26, 2021
Jun. 27, 2020
Operating activities:    
Net earnings $ 36,732,000 $ 11,721,000
Adjustments to reconcile net earnings to net cash provided by operating activities:    
Depreciation of fixed assets 36,278,000 37,353,000
Amortization of intangibles and deferred costs 2,096,000 2,516,000
Share-based compensation 3,252,000 3,421,000
Deferred income taxes (188,000) (426,000)
(Gain) loss on marketable securities (926,000) 1,746,000
Plant shutdown impairment costs 0 5,072,000
Other (305,000) (309,000)
Changes in assets and liabilities net of effects from purchase of companies    
(Increase) decrease in accounts receivable (27,940,000) 24,634,000
Increase in inventories (5,964,000) (3,751,000)
(Increase) decrease in prepaid expenses 5,710,000 (7,879,000)
Increase (decrease) in accounts payable and accrued liabilities 24,823,000 (7,478,000)
Net cash provided by operating activities 73,568,000 66,620,000
Investing activities:    
Payments for purchases of companies, net of cash acquired 0 (57,197,000)
Purchases of property, plant and equipment (34,456,000) (47,637,000)
Purchases of marketable securities 0 (6,103,000)
Proceeds from redemption and sales of marketable securities 54,191,000 54,125,000
Proceeds from disposal of property and equipment 2,079,000 2,852,000
Other 42,000 (72,000)
Net cash provided by (used in) investing activities 21,856,000 (54,032,000)
Financing activities:    
Payments to repurchase common stock 0 (8,972,000)
Proceeds from issuance of stock 17,178,000 6,300,000
Payments on capitalized lease obligations (48,000) (272,000)
Payment of cash dividend (32,719,000) (31,193,000)
Net cash used in financing activities (15,589,000) (34,137,000)
Effect of exchange rate on cash and cash equivalents 624,000 (885,000)
Net increase (decrease) in cash and cash equivalents 80,459,000 (22,434,000)
Cash and cash equivalents at beginning of period 195,809,000 192,395,000
Cash and cash equivalents at end of period $ 276,268,000 $ 169,961,000